Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT

QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.